FLAIR: Week 124 Results of Long-Acting Injectable Cabotegravir + Rilpivirine

July 18-21, 2021; Virtual
At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 257 KB
Released: July 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Dr Joseph Eron and Clinical Care Options (CCO): Weight gain in initial ART, GEMINI, ADVANCE trials, and more

Joseph J. Eron, Jr., MD Released: July 22, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

IAS 2021 report from Clinical Care Options (CCO): CUSTOMIZE study shows that HCPs think monthly injectable CAB + RTV LA is feasible and acceptable despite COVID-19 disruptions

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue